In vitro and in vivo evaluation of the effects of duloxetine on P-gp function

Human Psychopharmacology

Volumn 25, Issue 7-8, 2010, Pages 553-559

  Ruike, Zhao ^a   Junhua, Cao ^a   Wenxing, Peng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Caco 2; duloxetine; P glycoprotein; rhodamine123; talinolol

Indexed keywords

DULOXETINE; GLYCOPROTEIN P; RHODAMINE 123; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS; CACO-2 CELLS; DRUG INTERACTIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; THIOPHENES; YOUNG ADULT;

EID: 79951765145     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1152     Document Type: Article

References (24)

1. Carmine MP, Richard BK, Andrew M, Robert WK,. 2003. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 139: 1111-1118.
2. Dan P, Yaron D, Dina M, Rimona M,. 2004. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64: 7562-7569.
3. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K,. 2000. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and Hepatic CYP3A4. Clin Pharmacol Ther 68: 598-604. (Pubitemid 32059985)
4. Funakoshi S, Murakami T, Yumoto R, Kiribayashi Y, Takano M,. 2003. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and beta-methyldigoxin in rats. J Pharm Sci 92: 1455-1463. (Pubitemid 36792758)
5. Gottesman MM, Pastan I,. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427. (Pubitemid 23237876)
6. Hanelt M, Gareis M, Kollarczik B,. 1994. Cytotoxicity of Mycotoxin evaluated by the MTT cell-culture assay. Mycopathologia 128: 167-174.
7. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen J, Schinkel AH,. 2001. P-glycoprotein limits oral availability,brain,and fetal penetration of Saquinavir even with high doses of ritonavir. Mol Pharmacol 59: 806-813. (Pubitemid 32274009)
8. Johanna W, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE,. 2003. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204. (Pubitemid 36373851)
9. Juurlink DN, Mamdani MM, Kopp A, Herrmann N, Laupacis A,. 2005. A population-based assessment of the potential interaction between serotonin specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 59: 102-107. (Pubitemid 40040102)
10. Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan1 H-Y, Knadler MP,. 2003. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31: 1142-1150. (Pubitemid 37048286)
11. Laura M, Roberto M, Roberto C, Mario A, Maria AR,. 2007. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure. J Chromatogr B 856: 81-87.
12. Leibovitz A, Bilchinsky T, Gil I, Habot B,. 1998. Elevated serum digoxin level associated with coadministered fluoxetine. Arch Int Med 158: 1152-1153. (Pubitemid 28242322)
13. Nakumura T, Sakaeda T, Ohmoto N, Moriya Y, Komoto C, Shirakawa T, Gotoh A, Matsuo M, Okmura K,. 2003. Gene expression profiles of ABC transporters and Cytochrome P450 3A inCaco-2 and human colorectal cancer cell lines. Pharm Res 20: 324-327. (Pubitemid 36269742)
14. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV,. 2002. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36: 106-132.
15. Norton PA, Zinner NR, Yalcin I, Bump RC,. 2002. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187: 40-48. (Pubitemid 34800298)
16. Schwarz UI, Gramatté T, Krappweis J, Oertel R, Kirch W,. 2000. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38: 161-167. (Pubitemid 30193611)
17. Schwarz UI, Dresser GK, Oertel R, Kim RB,. 2001. Talinolol-verapamil interaction is not solely due to P-glycoprotein inhibition [abstract]. Clin Pharmacol Ther 69: P85. (Pubitemid 33787055)
18. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P,. 2004. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J. Pharm Sci 21: 69-75. (Pubitemid 38050205)
19. Wang RB, Kuo CL, Lien LL, Lien EJ,. 2003. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28: 203-228. (Pubitemid 36783098)
20. Weber CC, Kressmann S, Ott M, Fricker G, Muller WE,. 2005. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 38: 293-300. (Pubitemid 41815686)
21. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P,. 1996. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13: 514-522. (Pubitemid 26119052)
22. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW,. 1993. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8: 23-33. (Pubitemid 23011155)
23. Yasui-Furukori N, Kaneko S,. 2006. Digitalis intoxication induced by paroxetine co-administration. Lancet 367: 788. (Pubitemid 43326297)
24. Yu DK,. 1999. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39: 1203-1211. (Pubitemid 30644000)